Chicago, USA — November 30, 2025 — At RSNA 2025, the world’s most influential annual event in medical imaging, InferVision made another strong appearance, showcasing new breakthroughs in surgical planning, oncology assessment, and global ecosystem collaboration. This year, the company once again captured industry attention with several major innovations, reaffirming its leadership as a global AI healthcare company in both technological advancement and international deployment.
InferOperate automatic 3D reconstruction products Continue to Advance, Achieve Dual Market Access in Europe and the United States
InferVision’s InferOperate automatic 3D reconstruction products have reached major regulatory milestones: it has successfully obtained CE certification in Europe, UKCA certification in the United Kingdom, and FDA clearance in the United States—officially entering the world’s three major medical device markets. Building on these approvals, the product has already launched full-scale commercial deployment across multiple countries and has received consistent recognition from clinical teams.
InferVision’s AI offers capabilities such as automated segmentation, 3D reconstruction, preoperative planning, and interactive visualization for multiple organs and clinical pathways. With regulatory clearance now achieved across the U.S., Europe, the U.K., and China, the product’s global accessibility has been greatly expanded—marking that InferVision’s R&D and quality systems in intelligent surgery have reached world-class standards.
Launch of InferCare RECIST: Multi-Organ Tumor Response Assessment AI Makes Its RSNA Debut
This year, InferVision officially launched the new InferCare RECIST, an intelligent platform designed for tumor imaging follow-up and therapeutic response evaluation. It supports multi-organ, multi-time-point, and multi-dimensional lesion tracking and analysis.
Key capabilities include:
1. AI multi-dimensional lesion analysis: Automatically assesses diameter, volume, and other metrics.
2. Cross-timepoint lesion comparison: Clearly visualizes tumor progression or treatment response.
3. Automated structured reports: Generates richly illustrated, standardized RECIST evaluation reports.
4. Deep integration with hospital systems: Compatible with DICOM and HL7, supporting cross-campus oncology data management.
This product enhances accuracy and consistency in radiologic assessment and provides systematic support for oncology MDTs, preoperative evaluation, and neoadjuvant therapy assessment.
Deepening Global Ecosystem Collaboration: Partnering with Microsoft and NVIDIA to Build the Future of Intelligent Healthcare
InferVision continues strengthening its strategic collaborations with global tech leaders Microsoft and NVIDIA:
With Microsoft: AI Models Integrated into Microsoft Precision Imaging Network
InferVision’s AI models have been integrated into the Microsoft Precision Imaging Network (Microsoft + Nuance). Through cloud deployment, this enables accelerated, standardized, and widely accessible intelligent imaging workflows for healthcare institutions worldwide.
With NVIDIA: Joint Advancement of AI Medical Technology
InferVision leverages NVIDIA’s advanced MONAI framework and TensorRT-accelerated inference to enhance AI development across screening, diagnosis, surgical planning, and oncology analysis. The MONAI framework has improved InferVision’s R&D efficiency, while NVIDIA’s DLI training supports their rapid advancement of large-model technologies. Both companies remain committed to ongoing collaboration to offer high-quality medical AI solutions globally.
